• Corpus ID: 35233448

[A case of glomerulopathy associated with the vascular endothelial growth factor inhibitor bevacizumab].

  title={[A case of glomerulopathy associated with the vascular endothelial growth factor inhibitor bevacizumab].},
  author={Kotaro Haruhara and Nobuo Tsuboi and Masatsugu Nakao and Kentaro Koike and Akira Fukui and Yoichi Miyazaki and Tetsuya Kawamura and Makoto Ogura and Takashi Yokoo},
  journal={Nihon Jinzo Gakkai shi},
  volume={56 5},
The patient was a 73-year-old Japanese female diagnosed with stage IIIc primary peritoneal cancer. After undergoing total hysterectomy and bilateral oophorectomy, she received regimens consisting of paclitaxel (PTX) and carboplatin (CBDCA). She subsequently developed recurrence four years after the disease onset and was treated with PTX, CBDCA and the vascular endothelial growth factor (VEGF) inhibitor bevacizumab (Bev). Although clinical remission was maintained with the administration of Bev… 
VEGF modulation and renal effects: Case report and review of the literature
The case of a man with renal cell carcinoma who was treated with surgical section and later started on sunitinib and developed several acute and chronic medical problems, including some related to anti-VEGF toxicity, are presented.
Minimal change disease onset observed after bevacizumab administration
MCD should be considered in patients who develop nephrotic syndrome while exposed to antiangiogenic agents, especially in patients with inoperable Grade 3 astrocytoma who are treated with a combination of temozolomide and bevacizumab.
Renal failure during chemotherapy: renal biopsy for assessing subacute nephrotoxicity of pemetrexed
The optimal strategy with regard to renal complications in cancer patients is not clear, and acute or chronic loss in renal function generally leads to a new treatment line, possibly impairing the overall success of the treatment.
Sodium-glucose co-transporter 2 inhibitors and diabetic retinopathy: insights into preservation of sight and looking beyond
Evidence in other studies suggests that SGLT2i may confer retinoprotective effects via some of the same mechanisms in the aforementioned cardiorenal trials, which may represent opportunities for providers to decrease retinopathy in high-risk T2DM patients, reduce disease progression, and lower drug burden in diabetic Retinopathy patients.